Photo from wikipedia
Systemic therapy and transcatheter arterial chemoembolization (TACE) are the options recommended by the Chinese treatment guidelines for patients with HCCIVCTT. Tyrosine kinase inhibitors, such as lenvatinib, have been approved as… Click to show full abstract
Systemic therapy and transcatheter arterial chemoembolization (TACE) are the options recommended by the Chinese treatment guidelines for patients with HCCIVCTT. Tyrosine kinase inhibitors, such as lenvatinib, have been approved as first-line systemic therapies for advanced HCC. In addition, radiation therapy (RT) sheds some light on the treatment of HCC with portal vein tumor thrombus, as it provides significantly better postoperative survival outcomes. However, there are few scientific trials to support the effectiveness of combining TACE, lenvatinib and RT for the treatment of HCC-IVCTT.
Journal Title: Chinese Medical Journal
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!